October 15, 2024 EVerMed Inc. received investment from SPI as the 2nd closing of its seed round. With this capital increase, EVerMed will accelerate the development of its pipeline. SPI is a provider of high-quality integrated products and services to the pharmaceutical industry, from research equipment and bioresources for drug discovery, Read more…
August 9, 2024 EVerMed Inc. has raised 280 million yen in the 1st close of its seed round EVerMed Inc. has raised a total of 280 million yen through a third-party allotment of new shares to WUV 1 Limited Partnership (Shinjuku-ku, Tokyo; operating company: Waseda University Ventures, Inc.; CEO: Tetsuya Read more…
August 2, 2024 Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells EVerMed Inc. and KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Yutaka Ogihara, hereafter “KYORIN”) today announced that they have entered into an option agreement for drug discovery of extracellular vesicles Read more…